A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis

Gaurav Agnihotri, Katherine Shi, Peter A. Lio*

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Dupilumab, a monoclonal antibody that inhibits both interleukin (IL)-4 and IL-13 signaling, is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Patients with AD are already at increased risk of developing conjunctivitis, and clinical trials and case reports have shown a greater incidence of conjunctivitis in individuals with AD treated with dupilumab. As this is one of the more commonly reported side effects of this biologic agent, it is important that clinicians are aware of this association and advise patients receiving dupilumab to report signs of conjunctivitis. This review summarizes the risk factors, clinical features, and management options for patients with AD presenting with conjunctivitis after receiving dupilumab therapy.

Original languageEnglish (US)
Pages (from-to)311-318
Number of pages8
JournalDrugs in R and D
Volume19
Issue number4
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis'. Together they form a unique fingerprint.

  • Cite this